SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters
© 2021 Selvaraj et al..
A critical question in understanding the immunity to SARS-COV-2 is whether recovered patients are protected against re-challenge and transmission upon second exposure. We developed a Syrian hamster model in which intranasal inoculation of just 100 TCID50 virus caused viral pneumonia. Aged hamsters developed more severe disease and even succumbed to SARS-CoV-2 infection, representing the first lethal model using genetically unmodified laboratory animals. After initial viral clearance, the hamsters were re-challenged with 105 TCID50 SARS-CoV-2 and displayed more than 4 log reduction in median viral loads in both nasal washes and lungs in comparison to primary infections. Most importantly, re-challenged hamsters were unable to transmit virus to naïve hamsters, and this was accompanied by the presence of neutralizing antibodies. Altogether, these results show that SARS-CoV-2 infection induces protective immunity that not only prevents re-exposure but also limits transmission in hamsters. These findings may help guide public health policies and vaccine development and aid evaluation of effective vaccines against SARS-CoV-2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Life science alliance - 4(2021), 4 vom: 11. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Selvaraj, Prabhuanand [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 08.03.2021 Date Revised 30.03.2024 published: Electronic-Print GENBANK: NC_045512 Citation Status MEDLINE |
|---|
| doi: |
10.26508/lsa.202000886 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321340442 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321340442 | ||
| 003 | DE-627 | ||
| 005 | 20240331000130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26508/lsa.202000886 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM321340442 | ||
| 035 | |a (NLM)33574037 | ||
| 035 | |a (PII)e202000886 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Selvaraj, Prabhuanand |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2021 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a GENBANK: NC_045512 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Selvaraj et al. | ||
| 520 | |a A critical question in understanding the immunity to SARS-COV-2 is whether recovered patients are protected against re-challenge and transmission upon second exposure. We developed a Syrian hamster model in which intranasal inoculation of just 100 TCID50 virus caused viral pneumonia. Aged hamsters developed more severe disease and even succumbed to SARS-CoV-2 infection, representing the first lethal model using genetically unmodified laboratory animals. After initial viral clearance, the hamsters were re-challenged with 105 TCID50 SARS-CoV-2 and displayed more than 4 log reduction in median viral loads in both nasal washes and lungs in comparison to primary infections. Most importantly, re-challenged hamsters were unable to transmit virus to naïve hamsters, and this was accompanied by the presence of neutralizing antibodies. Altogether, these results show that SARS-CoV-2 infection induces protective immunity that not only prevents re-exposure but also limits transmission in hamsters. These findings may help guide public health policies and vaccine development and aid evaluation of effective vaccines against SARS-CoV-2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Lien, Christopher Z |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shufeng |e verfasserin |4 aut | |
| 700 | 1 | |a Stauft, Charles B |e verfasserin |4 aut | |
| 700 | 1 | |a Nunez, Ivette A |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Nimako, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, Mario A |e verfasserin |4 aut | |
| 700 | 1 | |a Starost, Matthew F |e verfasserin |4 aut | |
| 700 | 1 | |a Dennis, John U |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tony T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life science alliance |d 2018 |g 4(2021), 4 vom: 11. Apr. |w (DE-627)NLM286067536 |x 2575-1077 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2021 |g number:4 |g day:11 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26508/lsa.202000886 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2021 |e 4 |b 11 |c 04 | ||